The DOI matches its Crossref record; 195 of the 195 references it cites were found in a registry or an index.
Intravascular hemolysis and the pathophysiology of sickle cell disease
Open accessAbstract
flow, normoxia to hypoxia, isotonic to hypertonic environment, and acidotic to alkalotic milieu.Multiple components contribute to sickle hemoglobinopathy pathophysiology, including primary components arising from HbS polymerization and secondary components that are downstream effects of the HbS polymer. Understanding how these components' complexity is compounded by genetic and environmental modulation provides insight into the well-known clinical heterogeneity of sickle cell disease (SCD).A cardinal feature of SCD pathogenesis involves inflammation, accompanied by heterocellular leukocyte-platelet-erythrocyte-endothelial adhesive events that trigger vaso-occlusive episodes, acute organ ischemia, and reperfusion injury.Twenty-five years ago, epidemiological studies identified leukocytosis, lower HbF levels, and higher total hemoglobin levels as risk factors associated with increasing incidence of acute painful episodes and acute chest syndrome (ACS) (5).The independent association of high total hemoglobin levels with more pain, ACS events, and osteonecrosis was never mechanistically explained; however, it was implied to be a result of increased blood viscosity (Table 1).Recent epidemiological studies found that lower hemoglobin levels and higher intensity of steady-state hemolytic anemia consistently associate with vasculopathic complications of disease, such as stroke, leg ulcers, PH, priapism, and renal failure.This suggests that certain subphenotypes of SCD relate more to hemolytic anemia severity rather than sickle vaso-occlusion.The reader is referred to recent reviews describing the exceptional strides made in understanding the roles of red cell rigidity (6), inflammation, and cell adhesion in sickle vaso-occlusion (7-9).Here, we review the complementary role of intravascular hemolysis and anemia.Hemolysis is a fundamental feature of sickle cell anemia that contributes to its pathophysiology and phenotypic variability.Decompartmentalized hemoglobin, arginase 1, asymmetric dimethylarginine, and adenine nucleotides are all products of hemolysis that promote vasomotor dysfunction, proliferative vasculopathy, and a multitude of clinical complications of pulmonary and systemic vasculopathy, including pulmonary hypertension, leg ulcers, priapism, chronic kidney disease, and large-artery ischemic stroke.Nitric oxide (NO) is inactivated by cell-free hemoglobin in a dioxygenation reaction that also oxidizes hemoglobin to methemoglobin, a non-oxygen-binding form of hemoglobin that readily loses heme.Circulating hemoglobin and heme represent erythrocytic danger-associated molecular pattern (eDAMP) molecules, which activate the innate immune system and endothelium to an inflammatory, proadhesive state that promotes sickle vaso-occlusion and acute lung injury in murine models of sickle cell disease.Intravascular hemolysis can impair NO bioavailability and cause oxidative stress, altering redox balance and amplifying physiological processes that govern blood flow, hemostasis, inflammation, and angiogenesis.These pathological responses promote regional vasoconstriction and subsequent blood vessel remodeling.Thus, intravascular hemolysis represents an intrinsic mechanism for human vascular disease that manifests clinical complications in sickle cell disease and other chronic hereditary or acquired hemolytic anemias.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“As HbF falls and fewer F-cells are protected from HbS polymer damage, the propensity for vascular occlusion and intravascular hemolysis increases with the release of heme products into the circulation that scavenge nitric oxide causing endothelial damage and vasculopathy.[57][58][59]”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [58]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Once released, IL-1β binds to IL-1 receptor (IL-1R) on leukocytes and vascular cells, promoting a cascade of downstream events that lead to activation of neutrophils and platelets and upregulation of E-selectin, P-selectin, VCAM-1, ICAM-1, and chemokines such as IL-8 in endothelial cells, all of which promote vaso-occlusion (14, 17) (Figure 1).”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Vaso-occlusion contributes to ischemia-reperfusion injury, which, along with release of eDAMPs, promotes the progression of sterile inflammation (Figure 1d) in SCD (14, 17, 18).”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies in adults with SCD lend further support to the role of hemolysis by showing a link between the hyperhemolysis phenotype of SCD and stroke risk (17).”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Unequal protection by HbF across the gamut of sickle cell disease complications might be partially explained by differences in the pathophysiologic roots of these complications.57,58”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“Acute painful episodes and acute chest syndrome are a result of sickle vasoocclusion; HbF has the most noticeable beneficial effect on these subphenotypes.”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“Priapism, nephropathy, and sickle vasculopathy are associated with hemolysis.”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Survival in Patients with Primary Pulmonary Hypertension
D’Alonzo, G. E., Barst, R. J., Ayres, S. M., Bergofsky, E. H., Brundage, B. H., Detre, K. M., Fishman, A. P., Goldring, R. M., Groves, B. Μ., Kernis, J. T., et al. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-5-343 · Cited by 3,488
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320 · cited 1×
“Mortality Increases risk (19, 39, 42, 47, 49, 64, 188) Protective (189) Protective (190)”
Self-citationCerebrovascular accidents in sickle cell disease: rates and risk factors.
(1998) · PubMed · doi:10.1182/blood.v91.1.288 · Cited by 1,694
The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin
Rother, R. P., Bell, L. B., Hillmen, P., & Gladwin, M. T. (2005) · JAMA · doi:10.1001/jama.293.13.1653 · Cited by 1,565
Self-citationPain in Sickle Cell Disease: Rates and Risk Factors
Platt, O. S., Thorington, B. D., Brambilla, D. J., Milner, P. F., Rosse, W. F., Vichinsky, E., & Kinney, T. R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107043250103 · Cited by 1,546
Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease
Reiter, C. D., Wang, X., Tanus-Santos, J. E., Hogg, N., Cannon, R. O., Schechter, A. N., & Gladwin, M. T. (2002) · Nature Medicine · doi:10.1038/nm1202-799 · Cited by 1,330
Self-citationPulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease
Gladwin, M. T., Sachdev, V., Jison, M. L., Shizukuda, Y., Plehn, J. F., Minter, K., Brown, B., Coles, W. A., Nichols, J. S., Ernst, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035477 · Cited by 1,325
Self-citationCell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease
Reiter, C. D., Wang, X., Tanus-Santos, J. E., et al. (2002) · Nature Medicine · doi:10.1038/nm799 · Cited by 1,097
Kato, G. J., Gladwin, M. T., & Steinberg, M. H. (2007) · Blood Reviews · doi:10.1016/j.blre.2006.07.001 · Cited by 876
Self-citationCastro, O. L., Brambilla, D. J., Thorington, B. D., Reindorf, C. A., Scott, R., GILLETTE, P. N., Vera, J., & Levy, P. S. (1994) · Blood · doi:10.1182/blood.v84.2.643.643 · Cited by 805
Research works printed but not linked: 1
- 10.1038/nm1202-799 · DOI · Paper page
Cited by
Sorted by citations
Items 201–300 of 746
Hung, H.-Y., Chien, W., Chung, C., Kao, L., Chow, L., Chen, Y.-H., Kotlinska, J. H., Silberring, J., & Huang, E. Y. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.109102 · Cited by 18
Advances in new drug therapies for the management of sickle cell disease
Ataga, K. I., & Desai, P. C. (2018) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1471983 · Cited by 18
Liu, A., Jacobs, C., Paola Sebastiani, B., Glassberg, J., McCuskee, S., & Curtis, S. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06253-w · Cited by 16
Sickle cell disease in the new era: advances in drug treatment
Lee, M. T., & Ogu, U. O. (2022) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2022.103555 · Cited by 15
Mitochondria: Emerging Consequential in Sickle Cell Disease
Akhter, M. S., Hamali, H. A., Rashid, H., Dobie, G., Madkhali, A. M., Mobarki, A. A., Oldenburg, J., & Biswas, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030765 · Cited by 17
Vascular pathophysiology of sickle cell disease
Connes, P., Renoux, C., Joly, P., & Nader, É. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104202 · Cited by 16
Le, K., Wang, X., Chu, J., Lundt, M., Lee, Y. Y., Conrey, A. K., Frey, I., Giannini, S., Kosinski, P. A., Hausman, J. M., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013504 · Cited by 16
Yates, A. M., Joshi, V. M., Aygün, B., Moen, J., Smeltzer, M. P., Govindaswamy, D., Dowdy, J., Cotton, A., Kang, G., Ware, R. E., et al. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.27717 · Cited by 16
Grau, M., Nader, É., Jerke, M., Schenk, A., Renoux, C., Dietz, T., Collins, B., Bizjak, D. A., Joly, P., Bloch, W., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122155 · Cited by 16
Shah, P., Suriany, S., Kato, R. M., Bush, A., Chalacheva, P., Veluswamy, S., Denton, C. C., Russell, K., Khaleel, M., Forman, H. J., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.26003 · Cited by 16
Increased hemoglobin affinity for oxygen with GBT1118 improves hypoxia tolerance in sickle cell mice
Dufu, K., Williams, A. T., Muller, C. R., Walser, C., Lucas, A., Eaker, A. M., Alt, C., Cathers, B. E., Oksenberg, D., & Cabrales, P. (2021) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00048.2021 · Cited by 16
Targeting fetal hemoglobin expression to treat β hemoglobinopathies
Steinberg, M. H. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2066519 · Cited by 16
Self-citationRecent advances in “sickle and niche” research - Tribute to Dr. Paul S Frenette -
Torres, L. S., Asada, N., Weiss, M. J., Trumpp, A., Suda, T., Scadden, D. T., & Ito, K. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.06.004 · Cited by 19
Khaled, M. B., Ouederni, M., Mankai, Y., Rekaya, S., Fraj, I. B., Dhouib, N., Kouki, R., Mellouli, F., & Béjaoui, M. (2019) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2019.102374 · Cited by 16
Time to rethink haemoglobin threshold guidelines in sickle cell disease
Ballas, S. K., Kuypers, F. A., Gordeuk, V. R., Hankins, J. S., Thompson, A. A., & Vichinsky, E. P. (2021) · British Journal of Haematology · doi:10.1111/bjh.17578 · Cited by 17
Adeniyi, O., Baptista, R., Bhowmick, S., Cookson, A., Nash, R. J., Winters, A. L., Shen, J., & Mur, L. A. J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11082177 · Cited by 15
Incidence and predictors of priapism events in sickle cell anemia: a diary-based analysis
Idris, I. M., Abba, A., Galadanci, J. A., Aji, S. A., Jibrilla, A. U., Rodeghier, M., Kassim, A. A., Burnett, A. L. “., & DeBaun, M. R. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007285 · Cited by 15
A review on disease modifying pharmacologic therapies for sickle cell disease
Mahadevia, H. J., Ponvilawan, B., Madan, U., Sharma, P., Qasim, H., & Shrestha, A. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06216-1 · Cited by 17
Ayoola, O. O., Bolarinwa, R. A., Onakpoya, U. U., Adedeji, T. A., Onwuka, C. C., & Idowu, B. M. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018023267 · Cited by 15
Brzóska, T., Vats, R., Bennewitz, M. F., Tütüncüoğlu, E., Watkins, S. C., Ragni, M. V., Neal, M. D., Gladwin, M. T., & Sundd, P. (2020) · JCI Insight · doi:10.1172/jci.insight.139437 · Cited by 14
Self-citationGaartman, A. E., Sayedi, A. K., Gerritsma, J. J., de Back, T. R., Tuijn, C. F. J. V., Tang, M. W., Heijboer, H., de Heer, K., Biemond, B. J., & Nur, E. (2021) · British Journal of Haematology · doi:10.1111/bjh.17696 · Cited by 15
Novel Sickle Cell Disease Therapies: Targeting Pathways Downstream of Sickling
Morrone, K. A., Mitchell, W. B., & Manwani, D. G. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.04.007 · Cited by 15
Silveira, A. A. A., Mahon, O. R., Cunningham, C. C., Corr, E. M., Mendonça, R., Saad, S. T. O., Costa, F. F., Dunne, A., & Conran, N. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.3mia1118-418rr · Cited by 14
Free heme regulates placenta growth factor through NRF2-antioxidant response signaling
Kapetanaki, M. G., Gbotosho, O. T., Sharma, D., Weidert, F. L., Ofori-Acquah, S. F., & Kato, G. J. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.08.009 · Cited by 15
Self-citationNicolau, M., Vargas, S., Silva, M., Coelho, A., Ferreira, E., Mendonça, J., Vieira, L., Kjöllerström, P., Maia, R., Silva, R., et al. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03783-y · Cited by 15
Acute Hemolysis and Heme Suppress Anti-CD40 Antibody-Induced Necro-Inflammatory Liver Disease
Pfefferlé, M., Ingoglia, G., Schaer, C. A., Hansen, K., Schulthess, N., Humar, R., Schaer, D. J., & Vallelian, F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.680855 · Cited by 16
Homocysteine is associated with severity of microvasculopathy in sickle cell disease patients
Samarron, S. L., Miller, J. W., Cheung, A., Chen, P., Lin, X., Zwerdling, T., Wun, T., & Green, R. (2020) · British Journal of Haematology · doi:10.1111/bjh.16618 · Cited by 14
Anti-inflammatory cytokines in sickle cell disease
Alagbe, A. E., Domingos, I. F., Adekile, A. D., Blotta, M. H. S. L., & Santos, M. N. N. (2022) · Molecular Biology Reports · doi:10.1007/s11033-021-07009-1 · Cited by 17
Neurovascular Manifestations of Sickle Cell Disease
Zedde, M., Quaresima, M., Capodanno, I., Grisendi, I., Assenza, F., Napoli, M., Moratti, C., Pavone, C., Bonacini, L., Cecco, G. D., et al. (2024) · Hemato · doi:10.3390/hemato5030023 · Cited by 14
Almeida, L. E. F., Damsker, J. M., Albani, S. H., Afsar, N. M., Kamimura, S., Pratt, D. W., Kleiner, D. E., Quezado, M., Gordish‐Dressman, H., & Quezado, Z. (2018) · Scientific Reports · doi:10.1038/s41598-018-24274-6 · Cited by 14
Rivers, A. E., Jagadeeswaran, R., & Lavelle, D. (2018) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00440.2017 · Cited by 14
Zaidi, G. Z., Rosentsveyg, J., Fomani, K., Louie, J. E., & Koenig, S. J. (2019) · Journal of Intensive Care Medicine · doi:10.1177/0885066619874041 · Cited by 14
Strumph, K. L., Hafeman, M., Ranabothu, S., Gomes, W. A., Benitez, S., Kaskel, F. J., Manwani, D. G., & Mahgerefteh, J. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.28883 · Cited by 17
Stroke and presence of patent foramen ovale in sickle cell disease
Aggeli, C., Polytarchou, K., Dimitroglou, Y., Patsourakos, D., Delicou, S., Vassilopoulou, S., Tsiamis, E. G., & Tsioufis, K. (2021) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-021-02398-3 · Cited by 14
Gbotosho, O. T., Gollamudi, J., & Hyacinth, H. I. (2023) · Biomolecules · doi:10.3390/biom13020381 · Cited by 15
Olatunya, O. S., de Albuquerque, D. M., Santos, M. N. N., Kayode, T. S., Adekile, A. D., & Costa, F. F. (2020) · The Application of Clinical Genetics · doi:10.2147/tacg.s246607 · Cited by 16
Babu, B. V., Sridevi, P., Surti, S. B., Ranjit, M., Bhat, D., Sarmah, J., Sudhakar, G., & Sharma, Y. (2020) · PubMed Central · doi:10.12865/chsj.46.03.08 · Cited by 14
Mayer, C. L., Köeck, K., Hottmann, M., Redfern, A., Davis, M., Barth, A., Geng, X., Hoppe, C. C., & Yue, P. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03514-3 · Cited by 13
Nguyen, K., Mattè, A., Foresti, R., Federti, E., Kiger, L., Lefebvre, C., Hocini, H., Pelinski, Y., Kitagishi, H., Bencheikh, L., et al. (2024) · Blood · doi:10.1182/blood.2023023165 · Cited by 13
Kunz, J. B., & Tagliaferri, L. (2024) · Transfusion Medicine and Hemotherapy · doi:10.1159/000540149 · Cited by 14
Nyakundi, B. B., Erdei, J., Tóth, A., Balogh, E., Nagy, A., Nagy, B., Novák, L., Bognár, L., Paragh, G., Kappelmayer, J., et al. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/8929020 · Cited by 14
Integrative approaches to treating pain in sickle cell disease: Pre-clinical and clinical evidence
Sagi, V., Argueta, D. A., Kiven, S. B., & Gupta, K. (2020) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2020.102394 · Cited by 13
Deleschaux, C., Moras, M., Lefevre, S. D., & Ostuni, M. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155263 · Cited by 13
Batista, J. V. G. F., Arcanjo, G. D. S., Batista, T. H. C., Sobreira, M. J. D. V. C., de Santana, R. M., Domingos, I. F., Hatzlhofer, B. L. D., Falcão, D. A., Pereira‐Martins, D. A., Oliveira, J. M., et al. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04422-1 · Cited by 14
Chandu, A., Joshi, R. P., Gupta, P., Ramalingam, S., & Murugesan, S. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2199081 · Cited by 13
An integrated therapeutic approach to sickle cell disease management beyond infancy
Ribeil, J., Pollock, G., Frangoul, H., & Steinberg, M. H. (2023) · American Journal of Hematology · doi:10.1002/ajh.26956 · Cited by 13
Self-citationSickle cells and sickle trait in thrombosis
Kato, G. J. (2019) · Blood · doi:10.1182/blood.2019000694 · Cited by 13
Self-citationExploring the microvascular impact of red blood cell transfusion in intensive care unit patients
Hariri, G., Bourcier, S., Marjanovic, Z., Joffre, J., Lemarie, J., Lavillegrand, J., Charue, D., Duflot, T., Bigé, N., Baudel, J.-L., et al. (2019) · Critical Care · doi:10.1186/s13054-019-2572-9 · Cited by 13
MFSD7C protects hemolysis-induced lung impairments by inhibiting ferroptosis
Wang, H., You, X., Wang, J., Chen, X., Gao, Y., Wang, M., Zhang, W., Zhang, J., Yu, Y., Han, B., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52537-6 · Cited by 13
Jiang, Y., Li, Y., Wang, K., Feng, X., Zhao, W., Huang, C., Zhou, J., Yang, Z., Shen, C., & Han, L. (2025) · Advanced Materials · doi:10.1002/adma.202511733 · Cited by 12
Silva, M., & Faustino, P. (2023) · Antioxidants · doi:10.3390/antiox12111977 · Cited by 17
Red Blood Cells as Therapeutic Target to Treat Sickle Cell Disease
Bhatt, S., Argueta, D. A., Gupta, K., & Kundu, S. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0348 · Cited by 13
D’Alessandro, A., Le, K., Lundt, M., Li, Q., Dunkelberger, E. B., Cellmer, T., Worth, A. J., Patil, S., Huston, C., Grier, A., et al. (2024) · Haematologica · doi:10.3324/haematol.2023.284831 · Cited by 16
Tall, F. G., Martin, C., Ndour, E. H. M., Faës, C., Ly, I. D., Pialoux, V., Connes, P., Guéye, P. M., Diallo, R. N., Renoux, C., et al. (2020) · Antioxidants · doi:10.3390/antiox9090863 · Cited by 12
The NLRP3 inflammasome in macrophages is stimulated by cell‐free hemoglobin
Shaver, C. M., Landstreet, S. R., Pugazenthi, S., Scott, F. A., Putz, N. D., Ware, L. B., & Bastarache, J. A. (2020) · Physiological Reports · doi:10.14814/phy2.14589 · Cited by 12
Hydroxyurea and fetal hemoglobin effect on leg ulcers in patients with sickle cell disease
Tolu, S. S., Crouch, A. S., Choi, J., Gao, Q., Reyes-Gil, M., Ogu, U. O., Vinces, G., & Minniti, C. P. (2022) · Annals of Hematology · doi:10.1007/s00277-021-04635-4 · Cited by 12
Matos, C. F. D., Comont, T., Castex, M., Lafaurie, M., Walter, O., Moulis, G., Dion, J., & Cougoul, P. (2022) · Expert Review of Hematology · doi:10.1080/17474086.2022.2149488 · Cited by 13
Nasir, N. J. M., Heemskerk, H., Jenkins, J., Hamadee, N. H., Bunte, R. M., & Tucker‐Kellogg, L. (2023) · eLife · doi:10.7554/elife.85633 · Cited by 11
Jacob, S. A., Novelli, E. M., Isenberg, J. S., Garrett, M. E., Chu, Y., Soldano, K. L., Ataga, K. I., Telen, M. J., Ashley‐Koch, A. E., Gladwin, M. T., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24635 · Cited by 12
Self-citationImpaired Collateral Vessel Formation in Sickle Cell Disease
Okwan-Duodu, D. K., Hansen, L., Joseph, G., Lyle, A. N., Weiss, D., Archer, D. R., & Taylor, W. R. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.310771 · Cited by 12
Willen, S. M., McNeil, J. B., Rodeghier, M., Kerchberger, V. E., Shaver, C. M., Bastarache, J. A., Steinberg, M. H., DeBaun, M. R., & Ware, L. B. (2020) · American Journal of Hematology · doi:10.1002/ajh.25728 · Cited by 12
Self-citationDembélé, A. K., Lapouméroulie, C., Diaw, M., Tessougué, O., Offredo, L., Diallo, D. A., Diop, S., Élion, J., Colin, Y., Tharaux, P., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.17242 · Cited by 12
Abdelkader, A., Shaaban, M., Zahran, M. M., Mohammed, M. F., Ebrahim, A. M., & Galhoom, A. I. (2022) · International Journal of Clinical Practice · doi:10.1155/2022/9131423 · Cited by 12
An update on arginine in sickle cell disease
Benites, B. D., & Saad, S. T. O. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1591948 · Cited by 13
Discrepancy in patterns of myocardial involvement in beta-thalassaemia vs. sickle cell anaemia
AbdelMassih, A. F., Salama, K. M., Ghobrial, C., Haroun, B., & Rahman, M. A. (2019) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2019.1610836 · Cited by 12
Nakagawa, A., Cooper, M. K., Kost‐Alimova, M., Berstler, J., Yu, B., Berra, L. M., Klings, E. S., Huang, M., Heeney, M. M., Bloch, D. B., et al. (2022) · ACS Omega · doi:10.1021/acsomega.2c00541 · Cited by 11
Hemoglobin and End-Organ Damage in Individuals with Sickle Cell Disease
Ershler, W. B., Castro, L. M. D., Pakbaz, Z., Moynahan, A., Weycker, D. A., Delea, T. E., Agodoa, I., & Cong, Z. (2023) · Current Therapeutic Research · doi:10.1016/j.curtheres.2023.100696 · Cited by 11
Sahu, T. A., Pande, B., Verma, H. K., Bhaskar, L. V., Sinha, M., Sinha, R., & Rao, P. V. (2023) · Thalassemia Reports · doi:10.3390/thalassrep13030019 · Cited by 11
de Montalembert, M., Anderson, A. R., Costa, F. F., Inusa, B. P. D., Jastaniah, W. A., Kunz, J. B., Tinga, B., Ingoli, E., James, J., Hartfield, R., et al. (2024) · European Journal Of Haematology · doi:10.1111/ejh.14211 · Cited by 11
Vinhaes, C. L., Teixeira, R., Monteiro-Júnior, J. A. S., Tibúrcio, R., Cubillos-Angulo, J. M., Arriaga, M. B., Sabarin, A. G., de Souza, A. J., Silva, J. J., Lyra, I. M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-76075-5 · Cited by 11
Kidney iron deposition by R2* is associated with haemolysis and urinary iron
Denton, C. C., Detterich, J. A., Coates, T. D., & Wood, J. C. (2020) · British Journal of Haematology · doi:10.1111/bjh.17085 · Cited by 11
The different facets of sickle cell disease-related pulmonary hypertension
Prohaska, C. C., & Machado, R. F. (2021) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000795 · Cited by 11
Torres, L. S., Chweih, H., Fabris, F. C. Z., Gotardo, É. M. F., Leonardo, F. C., Saad, S. T. O., Costa, F. F., & Conran, N. (2022) · Cells · doi:10.3390/cells11071200 · Cited by 12
Individual Watershed Areas in Sickle Cell Anemia: An Arterial Spin Labeling Study
Stotesbury, H., Hales, P. W., Hood, A., Kölbel, M., Kawadler, J. M., Saunders, D. E., Sahota, S. K., Rees, D. C., Wilkey, O., Layton, M., et al. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.865391 · Cited by 11
The Evolving Landscape of Drug Therapies for Sickle Cell Disease
Rai, P., Desai, P. C., & Ataga, K. I. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.06.008 · Cited by 12
Gotardo, É. M. F., Brito, P. L., Gushiken, L. F. S., Chweih, H., Leonardo, F. C., Costa, F. F., & Conran, N. (2023) · Vascular Pharmacology · doi:10.1016/j.vph.2023.107176 · Cited by 10
Tamoxifen induces eryptosis through calcium accumulation and oxidative stress
Alfhili, M. A., Alyousef, A. M., & Alsughayyir, J. (2023) · Medical Oncology · doi:10.1007/s12032-023-02205-4 · Cited by 11
Gouraud, É., Charrin, E., Dubé, J. J., Ofori-Acquah, S. F., Martin, C., Skinner, S. C., Chatel, B., Boreau, A., Messonnier, L. A., Connes, P., et al. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/3765643 · Cited by 11
Bailey, D. M., Culcasi, M., Filipponi, T., Brugniaux, J. V., Stacey, B. S., Marley, C. J., Soria, R., Rimoldi, S. F., Černý, D., Rexhaj, E., et al. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.03.028 · Cited by 12
Shilo, N. R., & Morris, C. R. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1364989 · Cited by 12
Li, Y., Zhu, X., Hossain, M. A., Guy, C. R., Xu, H., Bungert, J., & Pace, B. S. (2018) · Haematologica · doi:10.3324/haematol.2017.185967 · Cited by 11
Improved quantitative detection of biotin‐labeled red blood cells by flow cytometry
Donnenberg, A. D., Kanias, T., Triulzi, D. J., Dennis, C. J., Meyer, E. M., & Gladwin, M. T. (2019) · Transfusion · doi:10.1111/trf.15354 · Cited by 11
Self-citationXu, Y., Li, J., Yang, M.-M., Wang, S., Xu, L., Ke, S., Ding, X.-M., Sun, W., & Gao, J. (2019) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001636 · Cited by 11
Liu, Y., Zhu, Y., Jiang, C., Su, Z., Yan, Y., Feng, B., Wen, M., Zhang, Y., Wang, X., Xu, Z., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02686-6 · Cited by 10
Chatzidavid, S., Flevari, P., Tombrou, I., Anastasiadis, G., & Dimopoulou, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094792 · Cited by 10
Rezoagli, E., Bombino, M., Ware, L. B., Carlesso, E., Rona, R., Grasselli, G., Pesenti, A. M., Bellani, G., & Foti, G. (2024) · ASAIO Journal · doi:10.1097/mat.0000000000002278 · Cited by 10
Inflammatory pathways and anti‐inflammatory therapies in sickle cell disease
Tozatto‐Maio, K., Rós, F. A., Weinlich, R., & Rocha, V. (2024) · HemaSphere · doi:10.1002/hem3.70032 · Cited by 10
Circulating biomarkers associated with pediatric sickle cell disease
Lekpor, C. E., Botchway, F. A., Driss, A., Bashi, A., Abrahams, A. O. D., Kusi, K. A., Futagbi, G., Alema‐Mensah, E., Agbozo, W. K., Solomon, W., et al. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1481441 · Cited by 11
Crosstalk Between Sickle Cell Disease and Ferroptosis
Russo, A., Patanè, G. T., Calderaro, A., Barreca, D., Tellone, E., & Putaggio, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083675 · Cited by 11
Management of Kidney Disease with Sickle Cell Disease
Abbasi, M., Srivastava, A., & Saraf, S. L. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000804 · Cited by 11
Placenta growth factor mediated gene regulation in sickle cell disease
Kalra, V. K., Zhang, S., Malik, P., & Tahara, S. M. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.08.008 · Cited by 10
Inflammatory Dendritic Cells Contribute to Regulate the Immune Response in Sickle Cell Disease
Sesti‐Costa, R., Borges, M. D., Lanaro, C., de Albuquerque, D. M., Saad, S. T. O., & Costa, F. F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.617962 · Cited by 9
Lins, C. F., Salmón, C. E. G., de Souza, L. A., Moraes, R. D. S., Silva‐Pinto, A. C., Matos, M. A., & Nogueira‐Barbosa, M. H. (2021) · Academic Radiology · doi:10.1016/j.acra.2021.06.006 · Cited by 10
Chambliss, C., Stiles, J. K., & Gee, B. E. (2022) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2022.106912 · Cited by 10
Oyedeji, C. I., Hodulik, K. L., Telen, M. J., & Strouse, J. J. (2023) · Drugs & Aging · doi:10.1007/s40266-023-01014-8 · Cited by 12
Alghareeb, S. A., Alsughayyir, J., & Alfhili, M. A. (2023) · Pharmaceuticals · doi:10.3390/ph16121681 · Cited by 10
Hakami, F., Alhazmi, E. A., Busayli, W. M., Althurwi, S., Darraj, A. M., Alamir, M. A., Hakami, A., Othman, R. A., Moafa, A. I., Mahasi, H. A., et al. (2023) · Cureus · doi:10.7759/cureus.50577 · Cited by 10
Sickle cell anaemia and the experiences of young people living with the condition
Foster, N., & Ellis, M. J. (2018) · Nursing Children and Young People · doi:10.7748/ncyp.2018.e935 · Cited by 10
Patrolling monocytes in sickle cell hemolytic conditions
Liu, Y., Zhong, H., Vinchi, F., Mendelson, A., & Yazdanbakhsh, K. (2019) · Transfusion Clinique et Biologique · doi:10.1016/j.tracli.2019.02.004 · Cited by 10
Donnenberg, A. D., Kanias, T., Triulzi, D. J., Dennis, C. J., Moore, L. R., Meyer, E. M., Sinchar, D. J., Kiss, J. E., Normolle, D. P., & Gladwin, M. T. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.04.052 · Cited by 10
Self-citation
Metadata
- Authors
- Kato, G. J., Steinberg, M. H., & Gladwin, M. T.
- Affiliations
- University of Pittsburgh (US)
- Boston University (US)
- Corresponding author
- Gladwin, Mark T.
- Venue
- Journal of Clinical Investigation
- Published
- 2017-03-01
- Volume
- 127
- Issue
- 3
- Pages
- 750-760
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5330745
- OpenAlex
- W2592339311
- Semantic Scholar
- 0c9beb4e3a557982862ac3ec381a89baab12ceae
- Cited by
- 748
- References
- 193
- Citations by year
- 2026: 90 · 2025: 81 · 2024: 76 · 2023: 65 · 2022: 116 · 2021: 81 · 2020: 87 · 2019: 76 · 2018: 53 · 2017: 21
- FWCI
- 9.15
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Patient-Centered Outcomes Research Institute
- University of Pittsburgh
- Hemophilia Center of Western Pennsylvania
- National Institutes of Health (HL098032)
- National Heart, Lung, and Blood Institute (R01HL087681, R01HL068970, P01HL103455, RC2HL101212, R01HL121386, U01HL107443, T32HL007501, R01HL125886, R01HL098032, T32HL110849)
- National Institute on Minority Health and Health Disparities (R01MD009162)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
- Health Sciences › Medicine › Hematology › Blood properties and coagulation
- Keywords
- intravascular hemolysis, sickle cell disease, free hemoglobin, nitric oxide, methemoglobin, heme, arginase-1, asymmetric dimethylarginine, adenine nucleotides, pulmonary hypertension, inflammation
- MeSH terms
- Anemia, Sickle Cell, Hemolysis, Humans, Methemoglobin, Nitric Oxide, Vascular Diseases, Vasomotor System
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
